Real World Evidence in Health Technology Assessments

Thursday, April 23, 2026

Why does the same therapy achieve full access in one market but face restrictions or delays in another?

The answer goes beyond clinical data. Across global markets, health technology assessment (HTA) bodies make structured tradeoffs between clinical benefit, cost, population need, and uncertainty to determine access. These decisions reflect system priorities as much as evidence itself.

Our experts will break down how HTA decisions are actually made, where real-world evidence (RWE) has the greatest influence, and why these dynamics matter for U.S. stakeholders. As payer and policy environments evolve, similar decision frameworks are already taking shape in the U.S., shaping how value is assessed and access is determined.

Why Watch:
In this session, you will learn how to:

• Understand why access decisions differ across global markets
• Recognize how those same dynamics are emerging in the U.S.
• Adapt evidence strategies to align with real-world decision-making